Surgical wide local excision (WLE) remains the current standard of care for primary cutaneous melanoma. WLE is an elective procedure that aims to achieve locoregional disease control with minimal functional and cosmetic impairment. Despite several prospective randomised trials, the optimal extent of excision margin remains controversial, and this is reflected in the persistent lack of consensus in guidelines globally. Furthermore, there is now the added difficulty of interpreting existing trial data in the context of the evolving role of surgery in the management of melanoma, with our increased understanding of clinicopathologic and genomic prognostic markers leading to the often routine use of sentinel node biopsy (SNB) as a staging procedure, in addition to the development of adjuvant systemic therapies for high-risk disease. An ongoing trial, MelMarT-II, has been designed with the aim of achieving a definitive answer to guide this fundamental surgical decision.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10930506 | PMC |
| http://dx.doi.org/10.3390/cancers16050895 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intralesional injection of CpG ODNs complexed with glatiramer acetate mitigates systemic cytokine toxicities and synergistically advances checkpoint blockade efficacy.
Drug Deliv Transl Res
January 2025
Kinimmune, Inc. St. Louis, 63141, Missouri, USA.
PD-L1/PD-1 checkpoint inhibitors (CPIs) are mainstream agents for cancer immunotherapy, but the prognosis is unsatisfactory in solid tumor patients lacking preexisting T-cell reactivity. Adjunct therapy strategies including the intratumoral administration of immunostimulants aim to address this limitation. CpG oligodeoxynucleotides (ODNs), TLR9 agonists that can potentiate adaptive immunity, have been widely investigated to tackle PD-L1/PD-1 resistance, but clinical success has been hindered by inconsistent efficacy and immune-related toxicities caused by systemic exposure.
View Article and Find Full Text PDFCarbapenem-resistant uses mucus metabolism to facilitate gastrointestinal colonization.
mBio
January 2025
Department of Microbiology, Genetics, & Immunology, Michigan State University, East Lansing, Michigan, USA.
The emergence and global spread of carbapenem-resistant complex species present a pressing public health challenge. Carbapenem-resistant spp. cause a wide variety of infections, including septic shock fatalities in newborns and immunocompromised adults.
View Article and Find Full Text PDFAssessing and alleviating pain in animals involved in research is critically important. However, the effective implementation of pain management depends on the knowledge and attitudes of the personnel involved. Following a Federation of European Laboratory Animal Science Associations 'Pain in Mice' working group initiative, a questionnaire to survey current practices concerning analgesic use in laboratory mice was distributed to several professional groups in the field of laboratory animal science.
View Article and Find Full Text PDFImplementing Food as Medicine During COVID-19: Produce Prescriptions and Integrative Group Medical Visits in Federally Qualified Health Centers.
Glob Adv Integr Med Health
January 2025
Alameda County Health, San Leandro, CA, USA.
Background: Food as Medicine is a rapidly developing area of health care in the United States, aimed at concurrently addressing nutrition-sensitive chronic conditions and food and nutrition insecurity. Recipe4Health (R4H) is a Food as Medicine program with an integrative health equity focus. It provides prescriptions for locally grown produce ('Food Farmacy') with or without integrative group medical visits, alongside training for clinic staff.
View Article and Find Full Text PDFCost savings of reducing opioid prescribing for the treatment of people with low back pain in general practice: a modelling study.
Lancet Reg Health West Pac
January 2025
School of Public Health, Faculty of Medicine and Health, University of Sydney, NSW, 2006, Australia.
Background: Low back pain (LBP) is the leading cause of disability worldwide. Contrary to clinical guidelines, opioids are frequently prescribed early in the management of LBP in primary care, leading to potential harm and downstream healthcare costs. The objective of this study was to model the one-year impacts of strategies that reduce opioid prescribing for low back pain (LBP) in primary care on healthcare costs and overdose deaths Australia-wide and explore the potential for such strategies to be cost-neutral.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!